Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India.

Autor:	Vaswani B; Medical Oncology, Yashoda Cancer Institute, Secunderabad 500003, India., Bhagat S; Medical Services, Glenmark Pharmaceutical limited, Mumbai 400099, India. sagar.bhagat@glenmarkpharma.com., Patil S; Medical Services, Glenmark Pharmaceutical limited, Mumbai 400099, India., Barkate H; Medical Services, Glenmark Pharmaceutical limited, Mumbai 400099, India.
Jazyk:	angličtina
Zdroj:	World journal of clinical oncology [World J Clin Oncol] 2020 Aug 24; Vol. 11 (8), pp. 606-613.
DOI:	10.5306/wjco.v11.i8.606
Abstrakt:	Background: A new, oral fixed dose combination of highly selective neurokinin-1 receptor antagonist, netupitant with 5HT3 receptor antagonist, netupitant and palonosetron (NEPA) was approved in India for prevention of chemotherapy induced nausea and vomiting (CINV). Aim: To assess effectiveness of NEPA in real-world scenario. Methods: We retrospectively assessed the medical records and patient dairies of adult patients who received highly emetogenic or moderately emetogenic chemotherapy (HEC/MEC) and treated with NEPA (Netupitant 300 mg + Palanosetron 0.50 mg) for prevention of CINV. Complete response (CR) was defined as no emesis or no requirement of rescue medication in overall phase (0 to 5 d), acute phase (0-24 h) and delayed phase (2 to 5 d). Results: In 403 patients included in the analysis, mean age was 56.24 ± 11.11 years and 55.09% were females. Breast cancer (25.06%) was most common malignancy encountered. HEC and MEC were administered in 54.6% and 45.4% patients respectively. CR in overall phase was 93.79% whereas it was 98.01% in acute CINV and 93.79% in delayed CINV. Overall CR in HEC and MEC groups was 93.63% and 93.98% respectively. CR was more than 90% in different chemotherapy cycles except in group of patients of cycle 4 where CR was 88.88%. Conclusion: NEPA is a novel combination that is effective in preventing CINV in up to 93% cases treated with highly emetogenic or moderately emetogenic chemotherapy. This study brings the first real-life evidence of its effectiveness in India population. (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu